Epygen biotech announces funding from india government for development of a covid-19 vaccine using dyadic's licensed c1 protein production platform

Jupiter, fla., april 13, 2022 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company announced today that dyadic licensee, epygen biotech pvd, ltd., has received funding from the department of biotechnology, government of india, to advance an affordable covid-19 vaccine candidate through phase 1 and phase 2 clinical trials in india which utilizes dyadic's c1 protein production platform. epygen biotech is an indian biopharmaceutical company engaged in both research and manufacturing of therapeutic proteins for critical diseases and novel vaccines.
DYAI Ratings Summary
DYAI Quant Ranking